Anti‐inflammatory agents in atherosclerosis—and a need for reform: Extraordinary claims require extraordinary evidence

Journal of Internal Medicine · Published 2026-07-12 · DOI 10.1111/joim.70128

Free full text

Authors (1)

Kevin Jon Williams

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Williams, K. (2026). Anti‐inflammatory agents in atherosclerosis—and a need for reform: Extraordinary claims require extraordinary evidence. Journal of Internal Medicine. https://doi.org/10.1111/joim.70128

Related articles

• Acute clinical events and trajectories of frailty after age 60: A population‐based cohort study · Journal of Internal Medicine · 2026 · Same journal
• Blood biomarkers of Alzheimer's disease and 15‐year decline in cognitive and motor functions in older adults · Journal of Internal Medicine · 2026 · Same journal
• Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving field · Journal of Internal Medicine · 2026 · Same journal
• Fecal microbiota transplantation‐based treatment protocol for chronic insomnia disorder: A randomized, double‐blind, placebo‐controlled trial · Journal of Internal Medicine · 2026 · Same journal
• Epigenetic analyses suggest different pathways during pregnancy for development of type 1 diabetes in children with high versus low‐neutral human leukocyte antigen‐risk · Journal of Internal Medicine · 2026 · Same journal
• Collagen and microvascular alterations contribute to neuromuscular degeneration and disease progression in chronic intestinal pseudo‐obstruction · Journal of Internal Medicine · 2026 · Same journal
• Trends in celiac disease autoimmunity before and after the COVID‐19 pandemic · Journal of Internal Medicine · 2026 · Same journal
• Colorectal cancer screening and incidence and mortality of colorectal and other cancers in the United Kingdom · Journal of Internal Medicine · 2026 · Same journal
• The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities · Journal of Internal Medicine · 2026 · Same journal
• Flare risk after oral glucocorticoid bridging with methotrexate or intra‐articular bridging with triple therapy in early rheumatoid arthritis · Journal of Internal Medicine · 2026 · Same journal